Lynparza (Olaparib) is a potent (PARP-1 IC50 = 5nM) oral PARP1/2 inhibitor [156] whose therapeutic efficacy has recently led to the approval by the US FDA and the European commission (report on the FDA website) for the treatment of patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with BRCA1 or BRCA2 mutations. Here, PARP1 is linked to ovarian serous adenocarcinoma.